News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial

XIENCE 28 Study will evaluate whether patients at high risk of bleeding can safely receive blood thinners for as short as 28 days after receiving drug-eluting stent

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial

February 13, 2018 — Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of bleeding after implantation with a Xience everolimus-eluting coronary stent. The first patient was enrolled into the  XIENCE 28 GLOBAL DAPT study by Prof. Emanuele Barbato, M.D., Ph.D., a cardiologist at OLV-Hospital Aalst in Belgium.

Patients who receive a stent are generally prescribed blood-thinning medicines to reduce the risk of stent thrombosis. However, blood thinning medicines can increase the risk of bleeding for some patients due to factors such as older age, chronic use of anticoagulant medications, anemia and renal disease[1],[2].

"While blood thinning medicines are important to prevent clots after a stent is implanted, we want to limit the duration of these medications for people who are at high risk of bleeding," said Marco Valgimigli, M.D., Ph.D., associate professor of cardiology and senior interventional cardiologist at the Universitätsspital in Bern, Switzerland, and co-principal investigator of the study. "This trial will help determine if high-bleeding risk patients can safely reduce their duration of blood thinning medication to as short as 28 days."

In Europe, most patients at high risk of bleeding are currently treated with DAPT for three to six months after receiving a drug-eluting stent, according to EU treatment guidelines.[3]

XIENCE 28 GLOBAL is a prospective, single-arm, multi-center, open label, non-randomized study. The goal of the study is to assess whether one month of treatment with DAPT is non-inferior to at least six months of DAPT in high-bleeding risk patients. The primary endpoint is a composite rate of myocardial infarction, stent thrombosis, death, stroke or major bleeding between one and six months. Approximately 800 patients will be enrolled at 50 sites across Europe and Asia.

For more information: www.xiencestent.com/featured-trials

 

Related DAPT Content

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Key Interventional Cardiac Technology Updates to Prepare for TCT 2017

Questions Remain on DAPT Prolongation

 

References

1. Shanmugam VB, Harper R, Meredith I, Malaiapan Y, Psaltis PJ. An overview of PCI in the very elderly. J Geriatr Cardiol 2015;174−184.

2. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774–82.

3. Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx419.

Related Content

Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
Overlay Init